Yili Chuanning BiotechnologyLtd Resultados de beneficios anteriores
Pasado controles de criterios 5/6
Yili Chuanning BiotechnologyLtd has been growing earnings at an average annual rate of 47.4%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 12.9% per year. Yili Chuanning BiotechnologyLtd's return on equity is 18.1%, and it has net margins of 24.2%.
Información clave
47.4%
Tasa de crecimiento de los beneficios
53.0%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 11.3% |
Tasa de crecimiento de los ingresos | 12.9% |
Rentabilidad financiera | 18.1% |
Margen neto | 24.2% |
Última actualización de beneficios | 30 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely
Oct 11If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity
Jul 23We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease
May 31Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt
Feb 26Desglose de ingresos y gastos
Cómo gana y gasta dinero Yili Chuanning BiotechnologyLtd. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Sep 24 | 5,698 | 1,376 | 189 | 60 |
30 Jun 24 | 5,602 | 1,316 | 183 | 60 |
31 Mar 24 | 5,077 | 1,118 | 176 | 58 |
31 Dec 23 | 4,823 | 941 | 172 | 55 |
30 Sep 23 | 4,462 | 719 | 70 | 48 |
30 Jun 23 | 4,254 | 565 | 84 | 41 |
31 Mar 23 | 4,093 | 486 | 135 | 39 |
01 Jan 23 | 3,821 | 412 | 170 | 35 |
30 Sep 22 | 3,634 | 272 | 350 | 59 |
31 Mar 22 | 3,345 | 154 | 171 | 35 |
01 Jan 22 | 3,232 | 111 | 129 | 33 |
31 Dec 20 | 3,649 | 229 | 123 | 25 |
31 Dec 19 | 3,143 | 91 | 178 | 18 |
31 Dec 18 | 3,349 | 390 | 123 | 5 |
Ingresos de calidad: 301301 has high quality earnings.
Margen de beneficios creciente: 301301's current net profit margins (24.2%) are higher than last year (16.1%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 301301's earnings have grown significantly by 47.4% per year over the past 5 years.
Acelerando crecimiento: 301301's earnings growth over the past year (91.3%) exceeds its 5-year average (47.4% per year).
Beneficios vs. Industria: 301301 earnings growth over the past year (91.3%) exceeded the Biotechs industry 0.08%.
Rentabilidad financiera
Alta ROE: 301301's Return on Equity (18.1%) is considered low.